The treatment of neonatal respiratory distress syndrome with surfactant represents a
successful culmination of decades of basic and clinical research. In many babies, respiratory …

Since the identification of surfactant deficiency as the putative cause of the infant respiratory
distress syndrome (RDS) by Avery and Mead in 1959, our understanding of the role of …

Regardless of the cause, a common pathophysiological feature of patients with acute
respiratory distress syndrome is a dysfunction of the endogenous surfactant system …

Exogenous surfactant has been the primary life-saving therapy for respiratory distress
syndrome (RDS) of preterm infants for many years. More recently, early surfactant treatment …

Over the past three decades, evidence has accumulated to support the hypothesis that
exogenous surfactant administration may be an effective treatment for patients with the acute …

Exogenous surfactant therapy has been recognised as an approach to alleviating the
surfactant-deficient state for 3 decades. Natural and lipid-extracted surfactants derived from …

Surfactant treatments have been the standard of care for infants who have respiratory
distress syndrome (RDS) ever since the United States Food and Drug Administration …

Exogenous surfactant is one of only a handful of neonatal therapies that has a strong
evidence base, the product of countless basic and clinical studies over roughly 30 years …

Exogenous surfactant therapy has been part of the routine care of preterm neonates with
respiratory distress syndrome (RDS) since the beginning of the 1990s. Discoveries that led …

This chapter examines exogenous surfactant therapy and its utility in miti-gating clinical
acute lung injury (ALI) and the acute respiratory distress syndrome (ARDS). Extensive …